Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
investigational drug |
| gptkbp:administeredBy |
oral route
|
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
111358-88-4
|
| gptkbp:developedBy |
gptkb:Cephalon
|
| gptkbp:hasInChIKey |
QZJXODVZJZQXQJ-IBGZPJMESA-N
|
| gptkbp:hasMolecularFormula |
C27H30N2O3
|
| gptkbp:hasSMILES |
COC1=CC=C(C=C1)CC(CO)NC(CC2=CNC3=CC=CC=C32)CO
|
| gptkbp:hasUNII |
6T6J2J95FK
|
| gptkbp:heldBy |
gptkb:receptor_tyrosine_kinase
|
| https://www.w3.org/2000/01/rdf-schema#label |
lestaurtinib
|
| gptkbp:is_investigational_for |
gptkb:myelofibrosis
solid tumors myeloproliferative disorders |
| gptkbp:is_not_FDA_approved |
true
|
| gptkbp:IUPACName |
(R)-1-(2-hydroxy-3-(4-methoxyphenyl)propylamino)-3-(1H-indol-3-yl)propan-2-ol
|
| gptkbp:molecularWeight |
430.54 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL297
106723 119570 |
| gptkbp:synonym |
CEP-701
KT-5555 |
| gptkbp:target |
gptkb:JAK2
gptkb:FLT3 |
| gptkbp:used_in_clinical_trials_for |
gptkb:acute_myeloid_leukemia
|
| gptkbp:bfsParent |
gptkb:staurosporine
|
| gptkbp:bfsLayer |
7
|